In the upcoming years, the pulmonary arterial hypertension (PAH) market will expand due to the rising occurrences of cardiovascular and pulmonary illnesses and the aging population, which is prone to such medical conditions. Furthermore, the risks of hypertension and high blood pressure have increased due to changes in lifestyle, such as a lack of physical activity, excessive alcohol consumption, and bad eating habits. The market for pulmonary arterial hypertension (PAH) is expanding as a result of factors like this, the creation of novel orphan drugs and technologically advanced devices for the treatment of PAH, the growing public awareness of the readily available treatment options for PAH, and an innovative healthcare system.
Since the COVID-19 pandemic has had such a profound influence on nearly every business, its impacts are anticipated to have an adverse effect on that industry's growth throughout the projected period. Several shifts in consumer demand and behavior, purchasing patterns, supply chain rerouting, and substantial government activities have been observed globally. The COVID-19 epidemic has benefited the market for pulmonary arterial hypertension due to increased COVID-19 infections among patients who already have pulmonary artery hypertension. Significantly impacted by COVID-19 are the identification and management of pulmonary hypertension and the discovery of an increased mortality risk in patients with pulmonary artery hypertension.
Growing Prevalence of Pulmonary Arterial Hypertension to Drive Market Growth
The market for pulmonary arterial hypertension is expanding as pulmonary arterial hypertension (PAH) condition is becoming more common. During the projected period, it is anticipated that the growing prevalence of PAH disorders and the associated hospitalization of patients for treatment will increase demand for pertinent medications. According to research by the National Organization for Rare Disorders, Inc., there are 500–1000 new cases of PAH in the United States annually or 1–2 cases per million people, and comparable incidence rates are anticipated in Europe.
Side-Effects Associated with PAH to Limit Market Growth
The growth of the global market is projected to be hampered by side effects related to PAH medications. Vasodilators are typically recommended to treat PAH patients to widen and unblock clogged blood arteries. Studies show that vasodilators are associated with various adverse effects, such as edoema, heart palpitations, tachycardia, and chest pain. The U.S. Food and Drug Administration (USFDA) controls the use of this medication due to the significant negative effects associated with its usage in chronically ill patients. Additionally, producers of PAH medications that lower blood pressure and widen blood arteries must provide reasonable assurance regarding the security and efficiency of their products. Before going on sale, these medications need FDA approval in the United States.
By Drug Class
Based on drug class, the pulmonary arterial hypertension (PAH) market is segmented into endothelin receptor antagonists, SGC stimulators, PDE-5 inhibitors, prostacyclin & prostacyclin analogs and others. The prostacyclin & prostacyclin analogs categories dominated the market in 2022. High demand and expanding indications are two important elements that significantly impact the huge share. Uptravi, a product in the Prostacyclin and Prostacyclin Analogs category, was given FDA approval in July 2021 for intravenous use in people with pulmonary arterial hypertension. The SGC simulator market is anticipated to expand at a CAGR of more than 5%. By amplifying NO-sGC signaling, sGC stimulators can ensure that sGC is activated to its fullest potential. The sole medication in this class licensed for PAH is riciguat (Adempas from Bayer). Sales of Adempas increased by almost 50% in 2020 over 2019, showing strong demand.
By Route of Administration
Based on the route of administration, the pulmonary arterial hypertension (PAH) market is segmented into oral, intravenous/subscutaneous and others. The oral category dominated the market in 2022. This is because patients prefer the oral method of administration, and oral formulations for pulmonary arterial hypertension are becoming more widely available. Oral PAH medications include Letairis, Opsumit, Adcirca, and Revatio, to name a few. For instance, sales of Johnson & Johnson's Opsumit tablets were USD 1.6 billion in 2020. Compared to 2019, the sales reflected a year-over-year gain of 23.5%. Other reasons influencing the adoption of oral medication administration include patient safety, affordability, high efficacy, and quick drug delivery.
Based on type, the pulmonary arterial hypertension (PAH) market is segmented into innovative and generics. The innovative category dominated the market in 2022. Key patents expiring, more generic drugs being released, expanding demand in emerging regions, and initiatives by large firms are all significant reasons for the growth. For instance, Zydus Healthcare Limited gained FDA approval in April 2021 to market a generic version of Opsumit Macitentan Tablets.
By Distribution Channel
Based on distribution channels, the pulmonary arterial hypertension (PAH) market is segmented into hospitals, retail pharmacies and online pharmacies. The hospital category dominated the market in 2022. Hospital pharmacies work tirelessly to uphold the highest standards of pharmaceutical care and medication administration for patients. In this line of work, pharmacists administer medicines, do quality checks, generate and revise dosage forms, monitor, report drug safety, and create medication budgets.
North America is projected to hold the largest share of the pulmonary arterial hypertension (PAH) market over the forecast period. The sophisticated healthcare systems in the United States and Canada, which make it easier to get cutting-edge treatments, are to blame for a significant portion. Additionally, heightened awareness, a high number of diagnoses, and favorable government measures boost the expansion of the industry in this area. The presence of important businesses and a well-planned reimbursement mechanism support the local market expansion. On the other hand, the Asia Pacific pulmonary arterial hypertension (PAH) market is anticipated to grow significantly. This is because generic drug use is increasing, important pharmaceutical businesses are nearby, and the healthcare system is evolving. This improved the company's portfolio. The area's need for better healthcare services is also driven by the region's enormous population base and the expanding burden of diseases like HIV that cause PAH.
LIST OF KEY COMPANIES PROFILED:
- United Therapeutics Corporation
- Bayer; Gilead Sciences, Inc.
- Johnson & Johnson
- Viatris Inc.
- Sandoz Inc. (Novartis)
- Lupin Pharmaceuticals, Inc.
- Sun Pharmaceutical Industries, Inc.
- Teva Pharmaceuticals Inc.
- February 2022: The first "digital hub" in Saudi Arabia was established by German company Bayer to help treat pulmonary hypertension (PH). During the COVID-19 pandemic, the AAN Digital Hub fills in gaps in disease diagnosis and treatment. They simplify patient referrals online and facilitate knowledge sharing between general practitioners, specialists, and their patients.
- May 2019: Teva Pharmaceutical Industries Ltd. introduced a generic version of Gilead's Letairis (ambrisentan) tablets in the United States. An endothelin receptor antagonist called ambrisentan is prescribed to treat pulmonary arterial hypertension (PAH).
|Market Size in 2022
|USD 7.5 Billion
|Market Forecast in 2030
|USD 10.9 Billion
|Compound Annual Growth Rate
|Revenue (USD Million) and Volume (Kilo Tons)
|By Drug Class, By Route of Administration, By Type, By Distribution Channel and By Geography
|By Drug Class
|By Route of Administration
|By Distribution Channel